Proton pump inhibitors and gastric neoplasia.
Proton pump inhibitors (PPIs) are very effective in maintaining symptomatic and endoscopic remission of acid peptic disorders, such as gastro-oesophageal reflux disease. Side effects with respect to function and morphology of the gastric mucosa are common. Helicobacter pylori eradication can partially prevent and reverse these effects without impairing PPI therapy for gastro-oesophageal reflux disease. This makes long term PPI treatment a safe therapy for patients with acid peptic disorders. The potential side effects of such therapy are discussed here.
Kuipers
E J
EJ
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Centre, PO Box 2040, 3000 CA Rotterdam, the Netherlands. e.j.kuipers@erasmusmc.nl
D000897:Anti-Ulcer Agents / Q000009:adverse effects*; D005756:Gastritis / Q000150:complications / Q000382:microbiology; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D016481:Helicobacter Infections / Q000150:complications; D016480:Helicobacter pylori; D006801:Humans; D054328:Proton Pump Inhibitors; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000209:etiology*
D000897:Anti-Ulcer Agents; D054328:Proton Pump Inhibitors